|Videos|March 4, 2015

Treatments After Progression in DTC

Episodes in this series

EP. 1 Approval of Lenvatinib: More Options

EP. 2 Who Are the Best Candidates for TKIs?

EP. 3 Interpreting Whole Body Scans

EP. 4 Genetic Testing: What Role Do Mutations Play?

Now Playing

EP. 5 Treatments After Progression in DTC

EP. 6 When to Refer a Patient to a Medical Oncologist

EP. 7 Monitoring During Active Surveillance and Treatment

EP. 8 Key Findings From DECISION and SELECT Trials

EP. 9 Current and Future Targets in Thyroid Cancer

EP. 10 More Personalized Therapy Needed to Improve Survival

EP. 11 Medullary Thyroid Cancer: What is Available?

Stay up to date on the most recent and practice-changing oncology data

Related to this article

HNSCC | Image Credit: © G.Go - stock.adobe.com

October 4th, 2026

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.

Image by Creative Station & MJH Life Sciences With AI

September 24th, 2026

Study Shows Reprogramming Thyroid Tumors May Improve CAR-T Cell Therapy

MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.